Focus: VaxCyte is a public biotechnology company focused on developing next-generation conjugate and protein-based vaccines targeting infectious diseases. With 1,001-5,000 employees, the company is a mid-cap biotech player headquartered in San Carlos, California.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
18 added, 20 removed. Backfill posture.
VaxCyte offers a high-risk, high-reward opportunity for R&D-focused professionals betting on pneumococcal vaccine upside, but pre-revenue burn and pipeline concentration demand risk tolerance.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for VaxCyte
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from VaxCyte's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Ionetix Corp / DE / (CIK 0002108121) — CURRENT REPORT
CURRENT REPORT
PCVX SEC Filings - Vaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PCVX SEC Filings - Vaxcyte, Inc. 10-K, 10-Q, 8-K Forms Stock Titan
Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360
Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO Law360
Vaxcyte Inc Stock (ISIN: US92242T1016) Slides on Major Investor Stake Cut - AD HOC NEWS
Vaxcyte Inc Stock (ISIN: US92242T1016) Slides on Major Investor Stake Cut AD HOC NEWS
Vaxcyte Advances VAX 31 To Late Stage With Added Pipeline Potential - simplywall.st
Vaxcyte Advances VAX 31 To Late Stage With Added Pipeline Potential simplywall.st
8-K Filing: Vaxcyte, Inc. (PCVX) (CIK 0001649094) — EX-99.1
EX-99.1
Showing 6 of 8 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial.
A pentavalent vaccine targeting adhesins and metal-binding lipoproteins confers robust protection against enterococcal infections.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo